Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma:a comparison of axitinib alone and axitinib plus anti-PD-1 antibody  

作　　者：Jiwei Huang Yueming Wang Haoran Zhang Xiaoyi Hu Ping Wang Wen Cai Yichu Yuan Hao Zeng Jin Zhang Wen Kong Yiran Huang Shuo Wang Jianming Guo Qiang Wei Wei Xue 

机构地区：[1]Department of Urology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,P.R.China [2]Department of Urology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China [3]Department of Urology,Zhongshan Hospital,Fudan University,Shanghai 200032,P.R.China [4]Department of Urology,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310003,P.R.China [5]Department of Urology,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310009,P.R.China

出　　处：《Cancer Communications》2021年第10期1071-1074,共4页癌症通讯（英文）

基　　金：supported by Shanghai Science and Technology Commission Research Project(21ZR1438900);the Incubating Program for Clinical Research and Innovation of Renji Hospital(PYXJS16-008,PYIII20-07).

摘　　要：Dear editor,The prognosis of metastatic renal cell carcinoma(mRCC)has been significantly improvedwith the development and widespread use of vascular endothelial growth factor(VEGF)pathway inhibitors and mammalian target of rapamycin(mTOR)pathway inhibitors[1].For the past decade,the standard of care utilized in the first-line setting was VEGF-targeted therapies.Recently,the mRCC treatment landscape has rapidly changed with the exploration of combinations of immune checkpoint inhibitors(ICIs)and anti-VEGF agents[2,3].

关 键 词：METASTATIC treatment prognosis 

分 类 号：R73[医药卫生—肿瘤]